Trial Profile
A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Safety and Tolerability of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Lirentelimab (Primary)
- Indications Eosinophilic gastroenteritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Allakos
- 30 Mar 2023 Status changed from active, no longer recruiting to completed.
- 27 Oct 2021 Results (As of March 2021, n=25) assessing the long-term safety and efficacy of lirentelimab, an open-label extension (OLE) study, and present data by disease type (EG with or without EoD versus EoD without EG) through week 94, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021.
- 27 Oct 2021 Results of an analysis compared symptom responses of patients with new diagnoses (de novo patients) with those of patients with prior diagnoses of EG and/or EoD to lirentelimab in ENIGMA and an open-label extension study.presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021